GEOVAX LABS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.42 USD | -3.40% |
|
-5.33% | -73.78% |
Presentation Operator MessageOperator (Operator)Good day. My name is Jordan and I'll be your c...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Companyâs portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.42
USD
Average target price
105
USD
Spread / Average Target
+7,294.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -73.78% | 3.28M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- GOVX Stock
- News GeoVax Labs, Inc.
- Transcript : GeoVax Labs, Inc., Q2 2023 Earnings Call, Aug 09, 2023
